These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24083544)

  • 1. Family history and risk of ductal carcinoma in situ and triple negative breast cancer in a Han Chinese population: a case-control study.
    Zhou W; Pan H; Liang M; Xia K; Liang X; Xue J; Cheng L; Xue J; Chen S; Liu X; Ding Q; Ling L; Wang S
    World J Surg Oncol; 2013 Oct; 11():248. PubMed ID: 24083544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch1 single nucleotide polymorphism rs3124591 is associated with the risk of development of invasive ductal breast carcinoma in a Chinese population.
    Cao YW; Wan GX; Zhao CX; Hu JM; Li L; Liang WH; Li WQ; Li YC; Li YX; Du XM; Yu SY; Li F
    Int J Clin Exp Pathol; 2014; 7(7):4286-94. PubMed ID: 25120811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.
    Liao N; Zhang GC; Liu YH; Li XR; Yao M; Xu FP; Li L; Wu YL
    Pathol Res Pract; 2011 Jan; 207(1):1-7. PubMed ID: 21095069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.
    Ruszczyk M; Zirpoli G; Kumar S; Bandera EV; Bovbjerg DH; Jandorf L; Khoury T; Hwang H; Ciupak G; Pawlish K; Schedin P; Masso-Welch P; Ambrosone CB; Hong CC
    Cancer Causes Control; 2016 Feb; 27(2):183-98. PubMed ID: 26621543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cis-acting super-enhancer lncRNAs as biomarkers to early-stage breast cancer.
    Ropri AS; DeVaux RS; Eng J; Chittur SV; Herschkowitz JI
    Breast Cancer Res; 2021 Oct; 23(1):101. PubMed ID: 34717732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic landscape of ductal carcinoma in situ and association with progression.
    Lin CY; Vennam S; Purington N; Lin E; Varma S; Han S; Desa M; Seto T; Wang NJ; Stehr H; Troxell ML; Kurian AW; West RB
    Breast Cancer Res Treat; 2019 Nov; 178(2):307-316. PubMed ID: 31420779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer.
    Milne RL; Goode EL; García-Closas M; Couch FJ; Severi G; Hein R; Fredericksen Z; Malats N; Zamora MP; Arias Pérez JI; Benítez J; Dörk T; Schürmann P; Karstens JH; Hillemanns P; Cox A; Brock IW; Elliot G; Cross SS; Seal S; Turnbull C; Renwick A; Rahman N; Shen CY; Yu JC; Huang CS; Hou MF; Nordestgaard BG; Bojesen SE; Lanng C; Grenaker Alnæs G; Kristensen V; Børrensen-Dale AL; Hopper JL; Dite GS; Apicella C; Southey MC; Lambrechts D; Yesilyurt BT; Floris G; Leunen K; Sangrajrang S; Gaborieau V; Brennan P; McKay J; Chang-Claude J; Wang-Gohrke S; Radice P; Peterlongo P; Manoukian S; Barile M; Giles GG; Baglietto L; John EM; Miron A; Chanock SJ; Lissowska J; Sherman ME; Figueroa JD; Bogdanova NV; Antonenkova NN; Zalutsky IV; Rogov YI; Fasching PA; Bayer CM; Ekici AB; Beckmann MW; Brenner H; Müller H; Arndt V; Stegmaier C; Andrulis IL; Knight JA; Glendon G; Mulligan AM; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Meindl A; Heil J; Bartram CR; Schmutzler RK; Thomas GD; Hoover RN; Fletcher O; Gibson LJ; dos Santos Silva I; Peto J; Nickels S; Flesch-Janys D; Anton-Culver H; Ziogas A; Sawyer E; Tomlinson I; Kerin M; Miller N; Schmidt MK; Broeks A; Van 't Veer LJ; Tollenaar RA; Pharoah PD; Dunning AM; Pooley KA; Marme F; Schneeweiss A; Sohn C; Burwinkel B; Jakubowska A; Lubinski J; Jaworska K; Durda K; Kang D; Yoo KY; Noh DY; Ahn SH; Hunter DJ; Hankinson SE; Kraft P; Lindstrom S; Chen X; Beesley J; Hamann U; Harth V; Justenhoven C; ; Winqvist R; Pylkäs K; Jukkola-Vuorinen A; Grip M; Hooning M; Hollestelle A; Oldenburg RA; Tilanus-Linthorst M; Khusnutdinova E; Bermisheva M; Prokofieva D; Farahtdinova A; Olson JE; Wang X; Humphreys MK; Wang Q; Chenevix-Trench G; ; ; Easton DF
    Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2222-31. PubMed ID: 21795498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
    Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
    Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
    Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
    Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene amplification in ductal carcinoma in situ of the breast.
    Burkhardt L; Grob TJ; Hermann I; Burandt E; Choschzick M; Jänicke F; Müller V; Bokemeyer C; Simon R; Sauter G; Wilczak W; Lebeau A
    Breast Cancer Res Treat; 2010 Oct; 123(3):757-65. PubMed ID: 20033484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel biomarker C6orf106 promotes the malignant progression of breast cancer.
    Jiang G; Zhang X; Zhang Y; Wang L; Fan C; Xu H; Miao Y; Wang E
    Tumour Biol; 2015 Sep; 36(10):7881-9. PubMed ID: 25953261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.
    Claus EB; Stowe M; Carter D
    Breast Cancer Res Treat; 2003 Mar; 78(1):7-15. PubMed ID: 12611452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels.
    Evans MF; Vacek PM; Sprague BL; Stein GS; Stein JL; Weaver DL
    J Cell Biochem; 2020 Feb; 121(2):1736-1746. PubMed ID: 31595577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism in hOGG1 is associated with triple-negative breast cancer risk in Chinese Han women.
    Xie H; Xia K; Rong H; Chen X
    Breast; 2013 Oct; 22(5):707-12. PubMed ID: 23369609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors that influence contralateral prophylactic mastectomy election among women with ductal carcinoma in situ who were evaluated for BRCA genetic testing.
    Elsayegh N; Kuerer HM; Lin H; Gutierrez Barrera AM; Jackson M; Muse KI; Litton JK; Albarracin C; Afrough A; Hortobagyi GN; Arun BK
    Ann Surg Oncol; 2014 Oct; 21(11):3466-72. PubMed ID: 24796968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis.
    Liu X; Gu X; Sun L; Flowers AB; Rademaker AW; Zhou Y; Kiyokawa H
    BMC Cancer; 2014 Feb; 14():57. PubMed ID: 24485087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
    Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
    Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
    Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
    Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.